<p>Personalis (納斯達克：PSNL - 獲取免費報告) 的目標股價在週五發佈的一份報告中被 Needham &amp; Company LLC 的分析師從$5.50 上調至$7.25，據 Benzinga 報道。該公司目前對該股票給予&#34;買入&#34;評級。Needham &amp; Company LLC 的目標股價預計將使股價潛在上漲 24.36%。</p>
<p>另外，Lake Street Capital 在 4 月 30 日星期二的研究報告中開始對 Personalis 進行覆蓋。他們為該公司發行了&#34;買入&#34;評級，並設定了$4.00 的目標股價。</p>
<p><strong>查看我們對 PSNL 的最新分析</strong></p>
<h2>Personalis 股票表現</h2>
<p>納斯達克：PSNL 的股價在週五上漲了$0.76，達到$5.83。該股交易量為 4,918,409 股，相比平均交易量 655,506 股有所增加。Personalis 的 12 個月最低價為$0.89，最高價為$7.20。該公司的 50 天移動平均股價為$2.26，200 天移動平均股價為$1.71。該公司的市值為 3.0946 億美元，市盈率為-3.14，貝塔係數為 1.85。</p>
<p>Personalis (納斯達克：PSNL - 獲取免費報告) 上次公佈其財報是在 8 月 7 日星期三。該公司本季度每股虧損 ($0.24)，超過了每股虧損 ($0.34) 的共識預期$0.10。Personalis 的淨利潤率為-101.78%，淨資產回報率為-56.87%。該公司本季度收入為 2,258 萬美元，超過了共識預期的 1,981 萬美元。去年同期，該公司每股虧損 ($0.50)。作為一組，賣方分析師預計 Personalis 今年將發佈-1.17 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>大型投資者最近增加或減少了他們在該股票中的持股。Acadian Asset Management LLC 在第二季度將其在 Personalis 的持股增加了 6.7%。Acadian Asset Management LLC 現在擁有該公司的 1,057,956 股股票，價值$1,237,000，較之前增持了 66,128 股。ARK Investment Management LLC 在第二季度增加了其在 Personalis 的持倉 4.9%。ARK Investment Management LLC 現在擁有該公司的 6,361,886 股股票，價值$7,443,000，較之前增持了 296,413 股。Virtu Financial LLC 在第一季度購入了一筆新的 Personalis 股票，價值約為$41,000。Jacobs Levy Equity Management Inc.在第一季度將其在 Personalis 的持股增加了 144.7%。Jacobs Levy Equity Management Inc.現在擁有該公司的 821,657 股股票，價值$1,224,000，較上一季度增持了 485,822 股。最後，俄亥俄州公務員退休系統在第一季度購入了一筆新的 Personalis 股票，價值約為$29,000。對沖基金和其他機構投資者擁有該公司股票的 61.91%。</p>
<h2>關於 Personalis（獲取免費報告）</h2>
<p>Personalis, Inc.主要在美國、歐洲和亞太地區開發和推廣先進的癌症基因組檢測和分析。其檢測和分析被製藥公司用於轉化研究、生物標誌物發現和個性化癌症治療的開發，醫生使用先進檢測來檢測癌症復發、監測癌症演變，併為治療選擇提供見解。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>什麼是盈利驚喜？</li>
<li>京東的盈利驚喜：中國的前景好於預期</li>
<li>內部買入解釋：投資者需要了解的內容</li>
<li>沃倫·巴菲特最近的股票交易：值得關注的買入和賣出</li>
<li>一些最佳大市值股票是什麼？</li>
<li>Sea Limited 的電子商務和金融科技實力推動股價飆升</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 您尚未擁有的第一加密貨幣（來自 Crypto 101 Media）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2"/></p>
<h2>您現在是否應該投資$1,000 在 Personalis？</h2>
<p>在考慮 Personalis 之前，您會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Personalis 不在名單上。</p>
<p>儘管 Personalis 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PSNL

<p>Needham & Company LLC 將 Personalis（納斯達克股票代碼：PSNL）的目標股價從 0.50 美元上調至 0.25 美元，並維持對該股票的 “買入” 評級。這表明潛在上漲空間為 24.36%。該公司最近的交易表現顯示股價上漲至 0.83 美元，並報告的每股收益好於預期。機構投資者也增加了對 Personalis 的持股</p>

<p>Personalis (NASDAQ:PSNL - Get Free Report) had its price objective raised by analysts at Needham &amp; Company LLC from $5.50 to $7.25 in a note issued to investors on Friday, Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price objective would suggest a potential upside of 24.36% from the stock's current price.</p>
<div class="lb-trans"><p>Personalis (納斯達克：PSNL - 獲取免費報告) 的目標股價在週五發佈的一份報告中被 Needham &amp; Company LLC 的分析師從$5.50 上調至$7.25，據 Benzinga 報道。該公司目前對該股票給予&#34;買入&#34;評級。Needham &amp; Company LLC 的目標股價預計將使股價潛在上漲 24.36%。</p>
</div><p>Separately, Lake Street Capital assumed coverage on Personalis in a research note on Tuesday, April 30th. They issued a &#34;buy&#34; rating and a $4.00 price objective for the company.</p>
<div class="lb-trans"><p>另外，Lake Street Capital 在 4 月 30 日星期二的研究報告中開始對 Personalis 進行覆蓋。他們為該公司發行了&#34;買入&#34;評級，並設定了$4.00 的目標股價。</p>
</div><p><strong>View Our Latest Analysis on PSNL</strong></p>
<div class="lb-trans"><p><strong>查看我們對 PSNL 的最新分析</strong></p>
</div><h2>Personalis Stock Performance</h2>
<div class="lb-trans"><h2>Personalis 股票表現</h2>
</div><p>Shares of NASDAQ:PSNL traded up $0.76 on Friday, hitting $5.83. The stock had a trading volume of 4,918,409 shares, compared to its average volume of 655,506. Personalis has a twelve month low of $0.89 and a twelve month high of $7.20. The firm's 50 day moving average price is $2.26 and its 200-day moving average price is $1.71. The company has a market capitalization of $309.46 million, a price-to-earnings ratio of -3.14 and a beta of 1.85.</p>
<div class="lb-trans"><p>納斯達克：PSNL 的股價在週五上漲了$0.76，達到$5.83。該股交易量為 4,918,409 股，相比平均交易量 655,506 股有所增加。Personalis 的 12 個月最低價為$0.89，最高價為$7.20。該公司的 50 天移動平均股價為$2.26，200 天移動平均股價為$1.71。該公司的市值為 3.0946 億美元，市盈率為-3.14，貝塔係數為 1.85。</p>
</div><p>Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.10. Personalis had a negative net margin of 101.78% and a negative return on equity of 56.87%. The firm had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same period last year, the company posted ($0.50) EPS. As a group, sell-side analysts predict that Personalis will post -1.17 EPS for the current year.</p>
<div class="lb-trans"><p>Personalis (納斯達克：PSNL - 獲取免費報告) 上次公佈其財報是在 8 月 7 日星期三。該公司本季度每股虧損 ($0.24)，超過了每股虧損 ($0.34) 的共識預期$0.10。Personalis 的淨利潤率為-101.78%，淨資產回報率為-56.87%。該公司本季度收入為 2,258 萬美元，超過了共識預期的 1,981 萬美元。去年同期，該公司每股虧損 ($0.50)。作為一組，賣方分析師預計 Personalis 今年將發佈-1.17 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its holdings in shares of Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company's stock worth $1,237,000 after acquiring an additional 66,128 shares during the period. ARK Investment Management LLC raised its position in Personalis by 4.9% during the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company's stock valued at $7,443,000 after purchasing an additional 296,413 shares during the period. Virtu Financial LLC bought a new position in shares of Personalis during the first quarter valued at approximately $41,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company's stock valued at $1,224,000 after buying an additional 485,822 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Personalis in the first quarter worth approximately $29,000. Hedge funds and other institutional investors own 61.91% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了他們在該股票中的持股。Acadian Asset Management LLC 在第二季度將其在 Personalis 的持股增加了 6.7%。Acadian Asset Management LLC 現在擁有該公司的 1,057,956 股股票，價值$1,237,000，較之前增持了 66,128 股。ARK Investment Management LLC 在第二季度增加了其在 Personalis 的持倉 4.9%。ARK Investment Management LLC 現在擁有該公司的 6,361,886 股股票，價值$7,443,000，較之前增持了 296,413 股。Virtu Financial LLC 在第一季度購入了一筆新的 Personalis 股票，價值約為$41,000。Jacobs Levy Equity Management Inc.在第一季度將其在 Personalis 的持股增加了 144.7%。Jacobs Levy Equity Management Inc.現在擁有該公司的 821,657 股股票，價值$1,224,000，較上一季度增持了 485,822 股。最後，俄亥俄州公務員退休系統在第一季度購入了一筆新的 Personalis 股票，價值約為$29,000。對沖基金和其他機構投資者擁有該公司股票的 61.91%。</p>
</div><h2>About Personalis (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Personalis（獲取免費報告）</h2>
</div><p>Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.</p>
<div class="lb-trans"><p>Personalis, Inc.主要在美國、歐洲和亞太地區開發和推廣先進的癌症基因組檢測和分析。其檢測和分析被製藥公司用於轉化研究、生物標誌物發現和個性化癌症治療的開發，醫生使用先進檢測來檢測癌症復發、監測癌症演變，併為治療選擇提供見解。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Personalis</li>
<li>What is an Earnings Surprise?</li>
<li>JD.com Earnings Surprise: China’s Outlook Better Than Expected</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票</li>
<li>什麼是盈利驚喜？</li>
<li>京東的盈利驚喜：中國的前景好於預期</li>
<li>內部買入解釋：投資者需要了解的內容</li>
<li>沃倫·巴菲特最近的股票交易：值得關注的買入和賣出</li>
<li>一些最佳大市值股票是什麼？</li>
<li>Sea Limited 的電子商務和金融科技實力推動股價飆升</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 您尚未擁有的第一加密貨幣（來自 Crypto 101 Media）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9176&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Personalis right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 Personalis？</h2>
</div><p>Before you consider Personalis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Personalis 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級和表現最佳的研究分析師以及他們推薦給客户的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Personalis 不在名單上。</p>
</div><p>While Personalis currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Personalis 目前在分析師中有&#34;買入&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Personalis（納斯達克代碼：PSNL）的目標價被 Needham & Company LLC 上調至 7.25 美元